Imcyse Announces Completion of Enrollment in Phase 1 Clinical Trial of IMCY-0141
13 Sep 2023 //
ACCESSWIRE
Imcyse Announces Completion of Enrollment in Phase 2 IMPACT Trial of IMCY-0098
01 Mar 2023 //
ACCESSWIRE
Imcyse Begins Dosing in Adaptive Phase 1/2 Trial of Imotope IMCY-0141
13 Apr 2022 //
GLOBENEWSWIRE
Imcyse to Present at Oppenheimer 32nd Annual Healthcare Conference
14 Mar 2022 //
GLOBENEWSWIRE
Imcyse Reports +ve Immune Response from Phase 2 IMPACT Type 1 Diabetes Study
13 Jan 2022 //
GLOBENEWSWIRE
Imcyse appoints Gene Mack as Chief Financial Officer
08 Nov 2021 //
PHARMABIZ